Logo

GBT’s Oxbryta (voxelotor) Receives EC’s Approval for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease

Share this

GBT’s Oxbryta (voxelotor) Receives EC’s Approval for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease

Shots:

  • The EC has granted marketing authorization for Oxbryta in adult & pediatric patients aged ≥12yrs. as monothx. or in combination with hydroxycarbamide to treat hemolytic anemia due to SCD
  • The approval was based on the results from the P-III (HOPE) study which showed an improvement in Hb levels. The therapy showed a favorable safety profile with limited and transitory adverse reactions
  • Oxbryta has received marketing authorization in the EU member states, Iceland, Liechtenstein & Norway. The therapy also received PRIME designation from the EMA while the company has submitted an application to the MHRA for marketing authorization in Great Britain using the EC decision reliance procedure

to­  Ref: Globe Newswire | Image: GBT

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions